Competitive PressuresSignificant biosimilar competition to Ocrevus and more conservative assumptions related to the multiple sclerosis franchise have led to a decrease in the price target from $265 to $220.
Investor ConcernsThe stock has experienced a significant pullback, decreasing by 21% this year and around 50% since its 52-week high, due to investor concerns over competitive pressures.
Sales ExpectationsLeqembi's future sales guidance is below consensus expectations, indicating lower anticipated growth.